Results 141 to 150 of about 38,480 (291)

Transverse Sinus Hypoplasia as a Differential Diagnosis for Cerebral Vein Thrombosis: A Case Report

Clinical Case Reports, Volume 13, Issue 10, October 2025.
ABSTRACT We present a 43‐year‐old female who had a history of deep vein thrombosis (DVT) and pulmonary emboli and was diagnosed with DVT. The patient reported a headache and underwent an emergency CT scan, which revealed no intracranial hemorrhage (ICH).
Hamidreza Ashayeri, Fateme Javanali Azar, Hadi Vahedi, Ariodad Ranji‐Amjad, Ali Jafarizadeh   +4 more
wiley   +1 more source

Economic evaluation of apixaban for atrial fibrillation in costa Rica [PDF]

, 2013
A. Rosado-Buzzo, L. García-Mollinedo, G. Luna-Casas, Matthias Lutz, J.P. Bogantes, José Manuel Sobrino Heredia, Genoveva Cuesta, J.F. Mould   +7 more
openalex   +1 more source

Amiodarone‐Induced Pulmonary Toxicity in an Elderly Patient: A Case Report

Clinical Case Reports, Volume 13, Issue 10, October 2025.
ABSTRACT Amiodarone, a widely utilized and effective class III antiarrhythmic agent, carries a significant risk of severe organ toxicities, notably including the pulmonary system. This report details a case of an 82‐year‐old female who developed amiodarone‐induced pulmonary toxicity (APT) following 2 years of standard 200 mg daily maintenance therapy ...
Bal Krishna Subedi, Naveen Gautam, Anuja Upadhyay, Parikshit Chapagain, Daniel Bitetto   +4 more
wiley   +1 more source

Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis of Patients with Atrial Fibrillation in Greece [PDF]

, 2013
Kostas Athanasakis, D. Arzoumanidou, E. Karampli, E. Armelidou, Periklis Giovas, Evangelia Petrikkou, John Kyriopoulos   +6 more
openalex   +1 more source

Therapeutic Plasma Exchange Shows Greater Efficacy Than DFPP in Reducing FT3 and FT4 Levels in Thyrotoxicosis due to Amiodarone‐Induced Thyrotoxicosis Type 2

Journal of Clinical Apheresis, Volume 40, Issue 5, October 2025.
ABSTRACT The American Society for Apheresis (ASFA) recommendations only mention using therapeutic plasma exchange (TPE) to treat drug‐resistant thyroid storms. Double filtration plasmapheresis (DFPP) is a therapeutic apheresis procedure with the advantage of being semi‐selective, making it possible to limit albumin losses and reduce the volume of ...
Marion Gerbal, Olivier Gilly, Marie‐Alix Joyeux, Olivier Moranne   +3 more
wiley   +1 more source

Clinical characteristics of apixaban prescription in AF patients with single dose-reduction criterion: the ASPIRE (efficAcy and safety of aPixaban in rEal-world practice in Korean frail patients with atrial fibrillation) study

Frontiers in Cardiovascular Medicine
BackgroundData on off-label reduced dose risk among patients with atrial fibrillation (AF) who qualify for a single-dose reduction of apixaban is scarce.ObjectivesWe prospectively assessed apixaban dosing and clinical characteristics in AF patients ...
JungMin Choi, So-Ryoung Lee, So-Ryoung Lee, Soonil Kwon, Hyo-Jeong Ahn, Kyung-Yeon Lee, Jong-Sung Park, Jong-Il Choi, Sung Ho Lee, Jung Ho Heo, Il-Young Oh, Young Keun On, Hee Tae Yu, Kwang-No Lee, Nam-Ho Kim, Hyung Wook Park, Hyung Wook Park, Ki Hong Lee, Ki Hong Lee, Seung Yong Shin, Seil Oh, Seil Oh, Gregory Y. H. Lip, Gregory Y. H. Lip, Gregory Y. H. Lip, Seongwook Han, Eue-Keun Choi, Eue-Keun Choi   +27 more
doaj   +1 more source

Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia [PDF]

, 2013
Zanfina Ademi, Kumar Pasupathi, Danny Liew   +2 more
openalex   +1 more source

Assessing Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Incidence of Major Adverse Cardiovascular Events: A Retrospective Cohort Study

Pharmacoepidemiology and Drug Safety, Volume 34, Issue 10, October 2025.
ABSTRACT Purpose Clopidogrel, an antiplatelet agent used to prevent ischemic events, may interact with proton pump inhibitors (PPIs), especially omeprazole and esomeprazole, and reduce its effectiveness. The evidence surrounding this interaction remains controversial.
Aljoharah M. Algabbani, Sumaya N. Almohareb, Adel A. Alrwisan   +2 more
wiley   +1 more source

Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study

, 2008
Harry R. Büller, David Deitchman, Martin H. Prins, Annelise Segers   +3 more
openalex   +1 more source

Resolution of left atrial appendage thrombus with apixaban [PDF]

, 2013
Tohru Kawakami, Hiroko Kobayakawa, Hiroyoshi Ohno, Nobukiyo Tanaka, Hiroki Ishihara   +4 more
openalex   +1 more source